Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global GABA Receptor Agonist Drug Market by Type (Bamaluzole, Phenibut, Baclofen, Gaboxadol, Klonopin (clonazepam), Tiagbine), By Application (Attention Deficit Hyperactivity Disorder (ADHD), Psychiatric Disorders and Depression, Alzheimer, Epilepsy and Seizure, Anxiety and Sleep Disorders, Obesity and Alcoholism) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global GABA Receptor Agonist Drug Market by Type (Bamaluzole, Phenibut, Baclofen, Gaboxadol, Klonopin (clonazepam), Tiagbine), By Application (Attention Deficit Hyperactivity Disorder (ADHD), Psychiatric Disorders and Depression, Alzheimer, Epilepsy and Seizure, Anxiety and Sleep Disorders, Obesity and Alcoholism) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 317122 4200 Pharma & Healthcare 377 169 Pages 4.8 (36)
                                          

Industry Growth Insights published a new data on “GABA Receptor Agonist Drug Market”. The research report is titled “GABA Receptor Agonist Drug Market research by Types (Bamaluzole, Phenibut, Baclofen, Gaboxadol, Klonopin (clonazepam), Tiagbine), By Applications (Attention Deficit Hyperactivity Disorder (ADHD), Psychiatric Disorders and Depression, Alzheimer, Epilepsy and Seizure, Anxiety and Sleep Disorders, Obesity and Alcoholism), By Players/Companies Advicenne, AstraZeneca, Athena Drug Delivery Solutions, Biocodex, Elan Corporation, Eli Lilly and Company, H.LundBeck, Merck and Co, GlaxoSmithKline, NovaDel Pharma, Novartis, Advicenne, Osmotica Pharmaceutical, Pfizer, sanofi-aventis, VIVUS, XenoPort”.

Scope Of The Report

Report Attributes

Report Details

Report Title

GABA Receptor Agonist Drug Market Research Report

By Type

Bamaluzole, Phenibut, Baclofen, Gaboxadol, Klonopin (clonazepam), Tiagbine

By Application

Attention Deficit Hyperactivity Disorder (ADHD), Psychiatric Disorders and Depression, Alzheimer, Epilepsy and Seizure, Anxiety and Sleep Disorders, Obesity and Alcoholism

By Companies

Advicenne, AstraZeneca, Athena Drug Delivery Solutions, Biocodex, Elan Corporation, Eli Lilly and Company, H.LundBeck, Merck and Co, GlaxoSmithKline, NovaDel Pharma, Novartis, Advicenne, Osmotica Pharmaceutical, Pfizer, sanofi-aventis, VIVUS, XenoPort

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

169

Number of Tables & Figures

119

Customization Available

Yes, the report can be customized as per your need.


Global GABA Receptor Agonist Drug Industry Outlook


Global GABA Receptor Agonist Drug Market Report Segments:

The global GABA Receptor Agonist Drug market is segmented on the basis of:

Types

Bamaluzole, Phenibut, Baclofen, Gaboxadol, Klonopin (clonazepam), Tiagbine

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Attention Deficit Hyperactivity Disorder (ADHD), Psychiatric Disorders and Depression, Alzheimer, Epilepsy and Seizure, Anxiety and Sleep Disorders, Obesity and Alcoholism

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Advicenne
  2. AstraZeneca
  3. Athena Drug Delivery Solutions
  4. Biocodex
  5. Elan Corporation
  6. Eli Lilly and Company
  7. H.LundBeck, Merck and Co
  8. GlaxoSmithKline
  9. NovaDel Pharma
  10. Novartis
  11. Advicenne
  12. Osmotica Pharmaceutical
  13. Pfizer
  14. sanofi-aventis
  15. VIVUS
  16. XenoPort

Global GABA Receptor Agonist Drug Market Overview


Highlights of The GABA Receptor Agonist Drug Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Bamaluzole
    2. Phenibut
    3. Baclofen
    4. Gaboxadol
    5. Klonopin (clonazepam)
    6. Tiagbine
  1. By Application:

    1. Attention Deficit Hyperactivity Disorder (ADHD)
    2. Psychiatric Disorders and Depression
    3. Alzheimer
    4. Epilepsy and Seizure
    5. Anxiety and Sleep Disorders
    6. Obesity and Alcoholism
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the GABA Receptor Agonist Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global GABA Receptor Agonist Drug Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


GABA receptor agonist drugs are medications that bind to the GABA receptors and increase the activity of these receptors. This can result in decreased anxiety and improved mood.

Some of the major companies in the gaba receptor agonist drug market are Advicenne, AstraZeneca, Athena Drug Delivery Solutions, Biocodex, Elan Corporation, Eli Lilly and Company, H.LundBeck, Merck and Co, GlaxoSmithKline, NovaDel Pharma, Novartis, Advicenne, Osmotica Pharmaceutical, Pfizer, sanofi-aventis, VIVUS, XenoPort.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 GABA Receptor Agonist Drug Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 GABA Receptor Agonist Drug Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 GABA Receptor Agonist Drug Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the GABA Receptor Agonist Drug Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global GABA Receptor Agonist Drug Market Size & Forecast, 2020-2028       4.5.1 GABA Receptor Agonist Drug Market Size and Y-o-Y Growth       4.5.2 GABA Receptor Agonist Drug Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 Bamaluzole
      5.2.2 Phenibut
      5.2.3 Baclofen
      5.2.4 Gaboxadol
      5.2.5 Klonopin (clonazepam)
      5.2.6 Tiagbine
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Attention Deficit Hyperactivity Disorder (ADHD)
      6.2.2 Psychiatric Disorders and Depression
      6.2.3 Alzheimer
      6.2.4 Epilepsy and Seizure
      6.2.5 Anxiety and Sleep Disorders
      6.2.6 Obesity and Alcoholism
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global GABA Receptor Agonist Drug Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 GABA Receptor Agonist Drug Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 Bamaluzole
      9.6.2 Phenibut
      9.6.3 Baclofen
      9.6.4 Gaboxadol
      9.6.5 Klonopin (clonazepam)
      9.6.6 Tiagbine
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Attention Deficit Hyperactivity Disorder (ADHD)
      9.10.2 Psychiatric Disorders and Depression
      9.10.3 Alzheimer
      9.10.4 Epilepsy and Seizure
      9.10.5 Anxiety and Sleep Disorders
      9.10.6 Obesity and Alcoholism
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 Bamaluzole
      10.6.2 Phenibut
      10.6.3 Baclofen
      10.6.4 Gaboxadol
      10.6.5 Klonopin (clonazepam)
      10.6.6 Tiagbine
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Attention Deficit Hyperactivity Disorder (ADHD)
      10.10.2 Psychiatric Disorders and Depression
      10.10.3 Alzheimer
      10.10.4 Epilepsy and Seizure
      10.10.5 Anxiety and Sleep Disorders
      10.10.6 Obesity and Alcoholism
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 Bamaluzole
      11.6.2 Phenibut
      11.6.3 Baclofen
      11.6.4 Gaboxadol
      11.6.5 Klonopin (clonazepam)
      11.6.6 Tiagbine
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Attention Deficit Hyperactivity Disorder (ADHD)
      11.10.2 Psychiatric Disorders and Depression
      11.10.3 Alzheimer
      11.10.4 Epilepsy and Seizure
      11.10.5 Anxiety and Sleep Disorders
      11.10.6 Obesity and Alcoholism
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 Bamaluzole
      12.6.2 Phenibut
      12.6.3 Baclofen
      12.6.4 Gaboxadol
      12.6.5 Klonopin (clonazepam)
      12.6.6 Tiagbine
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Attention Deficit Hyperactivity Disorder (ADHD)
      12.10.2 Psychiatric Disorders and Depression
      12.10.3 Alzheimer
      12.10.4 Epilepsy and Seizure
      12.10.5 Anxiety and Sleep Disorders
      12.10.6 Obesity and Alcoholism
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 Bamaluzole
      13.6.2 Phenibut
      13.6.3 Baclofen
      13.6.4 Gaboxadol
      13.6.5 Klonopin (clonazepam)
      13.6.6 Tiagbine
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Attention Deficit Hyperactivity Disorder (ADHD)
      13.10.2 Psychiatric Disorders and Depression
      13.10.3 Alzheimer
      13.10.4 Epilepsy and Seizure
      13.10.5 Anxiety and Sleep Disorders
      13.10.6 Obesity and Alcoholism
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 GABA Receptor Agonist Drug Market: Competitive Dashboard
   14.2 Global GABA Receptor Agonist Drug Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 Advicenne
      14.3.2 AstraZeneca
      14.3.3 Athena Drug Delivery Solutions
      14.3.4 Biocodex
      14.3.5 Elan Corporation
      14.3.6 Eli Lilly and Company
      14.3.7 H.LundBeck, Merck and Co
      14.3.8 GlaxoSmithKline
      14.3.9 NovaDel Pharma
      14.3.10 Novartis
      14.3.11 Advicenne
      14.3.12 Osmotica Pharmaceutical
      14.3.13 Pfizer
      14.3.14 sanofi-aventis
      14.3.15 VIVUS
      14.3.16 XenoPort

Our Trusted Clients

Contact Us